- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07941453
Pneumatic Displacement With Anti-VEGF and Concomitant rtPA for PCV-related Submacular Hemorrhage (PACT-PCV)
The Added Value of Recombinant Tissue Plasminogen Activator (rtPA) in Pneumatic Displacement of Submacular Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy (PCV) With Concomitant Anti-VEGF Therapy: A Prospective Randomized Controlled Trial
The goal of this randomized clinical trial is to determine whether adding recombinant tissue plasminogen activator (rtPA), a clot-dissolving medicine, to gas injection and anti-VEGF treatment improves outcomes in people with submacular hemorrhage (SMH) caused by polypoidal choroidal vasculopathy (PCV).
The main questions it aims to answer are:
- Does adding rtPA increase the proportion of participants with complete displacement of blood from beneath the fovea, the center of the macula, at 1 week after treatment?
- Does adding rtPA improve vision at 6 months and reduce complications, particularly vitreous hemorrhage (bleeding into the gel inside the eye) within 1 month after treatment?
Researchers will compare two pneumatic displacement (PD) strategies: anti-VEGF treatment plus C3F8 gas and rtPA (triple PD) and anti-VEGF treatment plus C3F8 gas without rtPA (dual PD). This comparison will assess the additional benefits and risks of rtPA. The study will enroll 80 participants at a single center. Participants will be randomly assigned to one of the two groups, with an equal chance of receiving either treatment.
The primary outcome is complete SMH displacement at 1 week, defined as no remaining blood beneath the fovea on optical coherence tomography (OCT), a scan that produces detailed images of the retina. Secondary outcomes include changes in best-corrected vision at 6 months, vitreous hemorrhage within 1 month, retinal detachment and other serious complications during follow-up, and the number of anti-VEGF injections over 6 months.
Participants will:
- Undergo baseline eye examinations, vision testing, and retinal imaging.
- Receive injections of anti-VEGF medicine and C3F8 gas into the affected eye, with or without rtPA, according to their assigned group.
- Follow the prescribed face-down positioning instructions for 3 days after treatment.
- Attend follow-up visits at 1 week and at 1, 3, and 6 months after treatment for vision testing, eye examinations, and retinal imaging, and receive further anti-VEGF treatment as needed.
Study Overview
Status
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Fang Zheng
- Phone Number: +86 18258499106
- Email: tjmuzxf@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Fovea-involving submacular hemorrhage (SMH) secondary to polypoidal choroidal vasculopathy (PCV), with a hemorrhage area of ≥2 optic disc areas and a subfoveal clot thickness of ≥300 μm.
- An interval of ≤14 days between symptom onset and planned treatment.
- Willingness to participate in the study and provision of written informed consent.
Exclusion Criteria:
- Unwillingness to undergo pneumatic displacement (PD).
- A history of previous SMH.
- Untreated retinal tears, retinal degenerative lesions, or other ocular conditions that make PD unsuitable.
- Concurrent significant vitreous hemorrhage that interferes with postoperative examination and treatment outcome assessment.
- Previous vitrectomy or other ocular surgery that may affect macular structure or the assessment of visual function.
- Coexisting ocular diseases, such as severe cataract, glaucoma, or uveitis, that may interfere with postoperative visual acuity assessment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Triple PD (Anti-VEGF + Gas + rtPA)
Intravitreal injection of an anti-VEGF agent, intravitreal injection of rtPA (off-label), and intravitreal gas injection for pneumatic displacement. |
Intravitreal injection of an anti-VEGF agent (specific agent and dose per study protocol) as part of pneumatic displacement treatment for PCV-related submacular hemorrhage. Intravitreal injection of rtPA as an off-label adjunct to pneumatic displacement, administered only in the triple PD arm at the dose specified in the study protocol, to promote clot liquefaction and facilitate submacular hemorrhage displacement. Intravitreal gas injection (gas type and volume per study protocol) followed by post-injection positioning, performed to displace submacular hemorrhage away from the fovea. This procedure is used in both study arms. |
|
Active Comparator: Dual PD (Anti-VEGF + Gas)
Intravitreal injection of an anti-VEGF agent and intravitreal gas injection for pneumatic displacement. |
Intravitreal injection of an anti-VEGF agent (specific agent and dose per study protocol) as part of pneumatic displacement treatment for PCV-related submacular hemorrhage. Intravitreal gas injection (gas type and volume per study protocol) followed by post-injection positioning, performed to displace submacular hemorrhage away from the fovea. This procedure is used in both study arms. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of complete SMH displacement at 1 week after the procedure.
Time Frame: 1 week after procedure
|
No residual submacular hemorrhage in the foveal area on OCT. |
1 week after procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of vitreous hemorrhage (VH) and proportion undergoing vitrectomy due to VH within 1 month after the procedure
Time Frame: Within 1 month after the procedure
|
Incidence of vitreous hemorrhage within 1 month after the procedure and the proportion of participants requiring pars plana vitrectomy (PPV) because of vitreous hemorrhage. |
Within 1 month after the procedure
|
|
Incidence of severe postoperative complications, including retinal detachment
Time Frame: Within 3 months after the procedure
|
Incidence of severe complications after the procedure, including retinal detachment. |
Within 3 months after the procedure
|
|
Change in best-corrected visual acuity (BCVA) at 6 months
Time Frame: At 6 months after the procedure
|
Change from baseline in best-corrected visual acuity (BCVA) at 6 months after the procedure, to assess visual prognosis. |
At 6 months after the procedure
|
|
Macular anatomical outcomes at 6 months
Time Frame: At 6 months after the procedure
|
Recovery of macular anatomy at 6 months after the procedure, including central macular thickness (CMT) , pigment epithelium detachment (PED) volume, and SMH absorption/resolution, to assess anatomical prognosis. |
At 6 months after the procedure
|
|
Number of anti-VEGF injections within 6 months after the procedure
Time Frame: Within 6 months after the procedure
|
Total number of anti-VEGF injections administered within 6 months after the procedure. |
Within 6 months after the procedure
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Eye Diseases
- Uveal Diseases
- Choroid Diseases
- Metaplasia
- Choroidal Neovascularization
- Neovascularization, Pathologic
- Pathological Conditions, Signs and Symptoms
- Polypoidal Choroidal Vasculopathy
- Amino Acids, Peptides, and Proteins
- Proteins
- Biological Factors
- Hydrolases
- Enzymes
- Enzymes and Coenzymes
- Blood Proteins
- Endopeptidases
- Peptide Hydrolases
- Serine Endopeptidases
- Serine Proteases
- Plasminogen Activators
- Blood Coagulation Factors
- Tissue Plasminogen Activator
Other Study ID Numbers
- 2 0 2 6 - 0 6 5 2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.